Targeting COVID-19 (SARS-CoV-2) main protease through phytochemicals of Albizia lebbeck: molecular docking, molecular dynamics simulation, MM–PBSA free energy calculations, and DFT analysis
et al., Journal of Proteins and Proteomics, doi:10.1007/s42485-024-00136-w, Apr 2024
Quercetin for COVID-19
27th treatment shown to reduce risk in
July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
In silico study showing potential benefits of quercetin and other phytochemicals from Albizia lebbeck as SARS-CoV-2 main protease (Mpro) inhibitors. Using molecular docking, the authors identified four promising compounds: vicenin 2, myricetin, quercetin, and albigenic acid. 100ns molecular dynamics simulations demonstrated that these compounds significantly impacted the structure of Mpro, with quercetin showing a higher binding free energy than the positive control drug nelfinavir. Density functional theory studies revealed that vicenin 2 was the most reactive compound. The results suggest that vicenin 2, myricetin, and quercetin may be beneficial for COVID-19 by inhibiting the viral main protease.
87 preclinical studies support the efficacy of quercetin for COVID-19:
In silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,8,9,15,16,29,31,32,34,37,45,46,48,49,72 (and specifically the receptor binding domainB,5), MproC,4,5,8,9,13,15,17,19,21,23,25,27,30,31,34,37,41,43-45,49-52,69 , RNA-dependent RNA polymeraseD,5,7-9,15,39 , PLproE,9,44,52 , ACE2F,24,29,30,34,35,44,48 , TMPRSS2G,29, nucleocapsidH,9, helicaseI,9,36,41 , endoribonucleaseJ,46, NSP16/10K,12, cathepsin LL,33, Wnt-3M,29, FZDN,29, LRP6O,29, ezrinP,47, ADRPQ,45, NRP1R,48, EP300S,22, PTGS2T,30, HSP90AA1U,22,30 , matrix metalloproteinase 9V,38, IL-6W,28,42 , IL-10X,28, VEGFAY,42, and RELAZ,42 proteins, and inhibition of spike-ACE2 interactionAA,6.
In vitro studies demonstrate inhibition of the MproC,21,55,60,68 protein, and inhibition of spike-ACE2 interactionAA,56.
In vitro studies demonstrate efficacy in Calu-3AB,59, A549AC,28, HEK293-ACE2+AD,67, Huh-7AE,32, Caco-2AF,58, Vero E6AG,26,49,58 , mTECAH,61, RAW264.7AI,61, and HLMECAJ,6 cells.
Animal studies demonstrate efficacy in K18-hACE2 miceAK,64, db/db miceAL,61,71 , BALB/c miceAM,70, and rats26.
Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice70, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages11, may block ACE2-spike interaction and NLRP3 inflammasome, limiting viral entry and inflammation2, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity63.
1.
Abdelhameed et al., Phytochemical and antiviral investigation of Cynanchum acutum L. extract and derived semi-synthetic analogs targeting SARS-CoV-2 main protease, Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-025-00907-2.
2.
Manikyam et al., INP-Guided Network Pharmacology Discloses Multi-Target Therapeutic Strategy Against Cytokine and IgE Storms in the SARS-CoV-2 NB.1.8.1 Variant, Research Square, doi:10.21203/rs.3.rs-6819274/v1.
3.
Makoana et al., Integration of metabolomics and chemometrics with in-silico and in-vitro approaches to unravel SARS-Cov-2 inhibitors from South African plants, PLOS ONE, doi:10.1371/journal.pone.0320415.
4.
Bano et al., Biochemical Screening of Phytochemicals and Identification of Scopoletin as a Potential Inhibitor of SARS-CoV-2 Mpro, Revealing Its Biophysical Impact on Structural Stability, Viruses, doi:10.3390/v17030402.
5.
Rajamanickam et al., Exploring the Potential of Siddha Formulation MilagaiKudineer-Derived Phytotherapeutics Against SARS-CoV-2: An In-Silico Investigation for Antiviral Intervention, Journal of Pharmacy and Pharmacology Research, doi:10.26502/fjppr.0105.
6.
Moharram et al., Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials, PLOS ONE, doi:10.1371/journal.pone.0313616.
7.
Metwaly et al., Integrated study of Quercetin as a potent SARS-CoV-2 RdRp inhibitor: Binding interactions, MD simulations, and In vitro assays, PLOS ONE, doi:10.1371/journal.pone.0312866.
8.
Al balawi et al., Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study, Bioresources and Bioprocessing, doi:10.1186/s40643-024-00822-z.
9.
Haque et al., Exploring potential therapeutic candidates against COVID-19: a molecular docking study, Discover Molecules, doi:10.1007/s44345-024-00005-5.
10.
Pan et al., Decoding the mechanism of Qingjie formula in the prevention of COVID-19 based on network pharmacology and molecular docking, Heliyon, doi:10.1016/j.heliyon.2024.e39167.
11.
Xu et al., Quercetin inhibited LPS-induced cytokine storm by interacting with the AKT1-FoxO1 and Keap1-Nrf2 signaling pathway in macrophages, Scientific Reports, doi:10.1038/s41598-024-71569-y.
12.
Tamil Selvan et al., Computational Investigations to Identify Potent Natural Flavonoid Inhibitors of the Nonstructural Protein (NSP) 16/10 Complex Against Coronavirus, Cureus, doi:10.7759/cureus.68098.
13.
Sunita et al., Characterization of Phytochemical Inhibitors of the COVID-19 Primary Protease Using Molecular Modelling Approach, Asian Journal of Microbiology and Biotechnology, doi:10.56557/ajmab/2024/v9i28800.
14.
Wu et al., Biomarkers Prediction and Immune Landscape in Covid-19 and “Brain Fog”, Elsevier BV, doi:10.2139/ssrn.4897774.
15.
Raman et al., Phytoconstituents of Citrus limon (Lemon) as Potential Inhibitors Against Multi Targets of SARS‐CoV‐2 by Use of Molecular Modelling and In Vitro Determination Approaches, ChemistryOpen, doi:10.1002/open.202300198.
16.
Asad et al., Exploring the antiviral activity of Adhatoda beddomei bioactive compounds in interaction with coronavirus spike protein, Archives of Medical Reports, 1:1, archmedrep.com/index.php/amr/article/view/3.
17.
Irfan et al., Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study, BMC Infectious Diseases, doi:10.1186/s12879-024-09387-w.
18.
Yuan et al., Network pharmacology and molecular docking reveal the mechanisms of action of Panax notoginseng against post-COVID-19 thromboembolism, Review of Clinical Pharmacology and Pharmacokinetics - International Edition, doi:10.61873/DTFA3974.
19.
Nalban et al., Targeting COVID-19 (SARS-CoV-2) main protease through phytochemicals of Albizia lebbeck: molecular docking, molecular dynamics simulation, MM–PBSA free energy calculations, and DFT analysis, Journal of Proteins and Proteomics, doi:10.1007/s42485-024-00136-w.
20.
Zhou et al., Bioinformatics and system biology approaches to determine the connection of SARS-CoV-2 infection and intrahepatic cholangiocarcinoma, PLOS ONE, doi:10.1371/journal.pone.0300441.
21.
Waqas et al., Discovery of Novel Natural Inhibitors Against SARS-CoV-2 Main Protease: A Rational Approach to Antiviral Therapeutics, Current Medicinal Chemistry, doi:10.2174/0109298673292839240329081008.
22.
Hasanah et al., Decoding the therapeutic potential of empon-empon: a bioinformatics expedition unraveling mechanisms against COVID-19 and atherosclerosis, International Journal of Applied Pharmaceutics, doi:10.22159/ijap.2024v16i2.50128.
23.
Shaik et al., Computational identification of selected bioactive compounds from Cedrus deodara as inhibitors against SARS-CoV-2 main protease: a pharmacoinformatics study, Indian Drugs, doi:10.53879/id.61.02.13859.
24.
Wang et al., Investigating the Mechanism of Qu Du Qiang Fei 1 Hao Fang Formula against Coronavirus Disease 2019 Based on Network Pharmacology Method, World Journal of Traditional Chinese Medicine, doi:10.4103/2311-8571.395061.
25.
Singh et al., Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach, Research Square, doi:10.21203/rs.3.rs-3888947/v1.
26.
El-Megharbel et al., Chemical and spectroscopic characterization of (Artemisinin/Quercetin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats, PeerJ, doi:10.7717/peerj.15638.
27.
Akinwumi et al., Evaluation of therapeutic potentials of some bioactive compounds in selected African plants targeting main protease (Mpro) in SARS-CoV-2: a molecular docking study, Egyptian Journal of Medical Human Genetics, doi:10.1186/s43042-023-00456-4.
28.
Yang et al., Active ingredient and mechanistic analysis of traditional Chinese medicine formulas for the prevention and treatment of COVID-19: Insights from bioinformatics and in vitro experiments, Medicine, doi:10.1097/MD.0000000000036238.
29.
Chandran et al., Molecular docking analysis of quercetin with known CoVid-19 targets, Bioinformation, doi:10.6026/973206300191081.
30.
Qin et al., Exploring the bioactive compounds of Feiduqing formula for the prevention and management of COVID-19 through network pharmacology and molecular docking, Medical Data Mining, doi:10.53388/MDM202407003.
31.
Moschovou et al., Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein, International Journal of Molecular Sciences, doi:10.3390/ijms242115894.
32.
Pan (B) et al., Quercetin: A promising drug candidate against the potential SARS-CoV-2-Spike mutants with high viral infectivity, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2023.10.029.
33.
Ahmed et al., Evaluation of the Effect of Zinc, Quercetin, Bromelain and Vitamin C on COVID-19 Patients, International Journal of Diabetes Management, doi:10.61797/ijdm.v2i2.259.
34.
Thapa et al., In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.
35.
Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.
36.
Singh (B) et al., Flavonoids as Potent Inhibitor of SARS-CoV-2 Nsp13 Helicase: Grid Based Docking Approach, Middle East Research Journal of Pharmaceutical Sciences, doi:10.36348/merjps.2023.v03i04.001.
37.
Mandal et al., In silico anti-viral assessment of phytoconstituents in a traditional (Siddha Medicine) polyherbal formulation – Targeting Mpro and pan-coronavirus post-fusion Spike protein, Journal of Traditional and Complementary Medicine, doi:10.1016/j.jtcme.2023.07.004.
38.
Sai Ramesh et al., Computational analysis of the phytocompounds of Mimusops elengi against spike protein of SARS CoV2 – An Insilico model, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2023.125553.
39.
Corbo et al., Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196.
40.
Azmi et al., Utilization of quercetin flavonoid compounds in onion (Allium cepa L.) as an inhibitor of SARS-CoV-2 spike protein against ACE2 receptors, 11th International Seminar on New Paradigm and Innovation on Natural Sciences and its Application, doi:10.1063/5.0140285.
41.
Alanzi et al., Structure-based virtual identification of natural inhibitors of SARS-CoV-2 and its Delta and Omicron variant proteins, Future Virology, doi:10.2217/fvl-2022-0184.
42.
Yang (B) et al., In silico evidence implicating novel mechanisms of Prunella vulgaris L. as a potential botanical drug against COVID-19-associated acute kidney injury, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1188086.
43.
Wang (B) et al., Computational Analysis of Lianhua Qingwen as an Adjuvant Treatment in Patients with COVID-19, Society of Toxicology Conference, 2023, www.researchgate.net/publication/370491709_Y_Wang_A_E_Tan_O_Chew_A_Hsueh_and_D_E_Johnson_2023_Computational_Analysis_of_Lianhua_Qingwen_as_an_Adjuvant_Treatment_in_Patients_with_COVID-19_Toxicologist_1921_507.
44.
Ibeh et al., Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2023.101230.
45.
Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.
46.
Alavi et al., Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study, Biomedicines, doi:10.3390/biomedicines10123074.
47.
Chellasamy et al., Docking and molecular dynamics studies of human ezrin protein with a modelled SARS-CoV-2 endodomain and their interaction with potential invasion inhibitors, Journal of King Saud University - Science, doi:10.1016/j.jksus.2022.102277.
48.
Şimşek et al., In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108038.
49.
Kandeil et al., Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2, Pathogens, doi:10.3390/pathogens10060758.
50.
Rehman et al., Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19, Current Pharmaceutical Design, doi:10.2174/1381612826999201116195851.
51.
Sekiou et al., In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.
52.
Zhang et al., In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus, Journal of Integrative Medicine, doi:10.1016/j.joim.2020.02.005.
53.
Sisti et al., Evaluation of respiratory virus transmissibility and resilience from fomites: the case of 11 SARS-CoV-2 clinical isolates, Applied and Environmental Microbiology, doi:10.1128/aem.00774-25.
54.
Spinelli et al., Amphibian‐Derived Peptides as Natural Inhibitors of SARS‐CoV‐2 Main Protease (Mpro): A Combined In Vitro and In Silico Approach, Chemistry & Biodiversity, doi:10.1002/cbdv.202403202.
55.
Aguilera-Rodriguez et al., Inhibition of SARS-CoV-2 3CLpro by chemically modified tyrosinase from Agaricus bisporus, RSC Medicinal Chemistry, doi:10.1039/D4MD00289J.
56.
Emam et al., Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors, AMB Express, doi:10.1186/s13568-024-01739-8.
57.
Fang et al., Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19, Journal of Nanobiotechnology, doi:10.1186/s12951-024-02435-2.
58.
Roy et al., Quercetin inhibits SARS-CoV-2 infection and prevents syncytium formation by cells co-expressing the viral spike protein and human ACE2, Virology Journal, doi:10.1186/s12985-024-02299-w.
59.
DiGuilio et al., Quercetin improves and protects Calu-3 airway epithelial barrier function, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1271201.
60.
Zhang (B) et al., Discovery of the covalent SARS‐CoV‐2 Mpro inhibitors from antiviral herbs via integrating target‐based high‐throughput screening and chemoproteomic approaches, Journal of Medical Virology, doi:10.1002/jmv.29208.
61.
Wu (B) et al., SARS-CoV-2 N protein induced acute kidney injury in diabetic db/db mice is associated with a Mincle-dependent M1 macrophage activation, Frontiers in Immunology, doi:10.3389/fimmu.2023.1264447.
62.
Xu (B) et al., Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19, Proceedings of the National Academy of Sciences, doi:10.1073/pnas.2301775120.
63.
Fam et al., Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites, Scientific Reports, doi:10.1038/s41598-023-31764-9.
64.
Aguado et al., Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology, bioRxiv, doi:10.1101/2023.01.17.524329.
65.
Goc et al., Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.
66.
Munafò et al., Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase, Research Square, doi:10.21203/rs.3.rs-1149846/v1.
67.
Singh (C) et al., The spike protein of SARS-CoV-2 virus induces heme oxygenase-1: Pathophysiologic implications, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, doi:10.1016/j.bbadis.2021.166322.
68.
Bahun et al., Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols, Food Chemistry, doi:10.1016/j.foodchem.2021.131594.
69.
Abian et al., Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2020.07.235.
70.
Shaker et al., Anti-cytokine Storm Activity of Fraxin, Quercetin, and their Combination on Lipopolysaccharide-Induced Cytokine Storm in Mice: Implications in COVID-19, Iranian Journal of Medical Sciences, doi:10.30476/ijms.2023.98947.3102.
a.
The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b.
The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.
c.
The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
d.
RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
e.
The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
f.
The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
g.
Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
h.
The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
i.
The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
j.
The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
k.
The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
l.
Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
m.
Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
n.
The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
o.
Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
p.
The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
q.
The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
r.
Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
s.
EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
t.
Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
u.
Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
v.
Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
w.
The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
x.
The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
y.
Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
z.
RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
aa.
The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
ab.
Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ac.
A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ad.
HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ae.
Huh-7 cells were derived from a liver tumor (hepatoma).
af.
Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
ag.
Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ah.
mTEC is a mouse tubular epithelial cell line.
ai.
RAW264.7 is a mouse macrophage cell line.
aj.
HLMEC (Human Lung Microvascular Endothelial Cells) are primary endothelial cells derived from the lung microvasculature. They are used to study endothelial function, inflammation, and viral interactions, particularly in the context of lung infections such as SARS-CoV-2. HLMEC express ACE2 and are susceptible to SARS-CoV-2 infection, making them a relevant model for studying viral entry and endothelial responses in the lung.
ak.
A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
al.
A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
am.
A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Nalban et al., 26 Apr 2024, peer-reviewed, 5 authors.
In silico studies are an important part of preclinical research, however results may be very different in vivo.
DOI record:
{
"DOI": "10.1007/s42485-024-00136-w",
"ISSN": [
"2524-4663"
],
"URL": "http://dx.doi.org/10.1007/s42485-024-00136-w",
"alternative-id": [
"136"
],
"assertion": [
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Received",
"name": "received",
"order": 1,
"value": "21 November 2023"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Revised",
"name": "revised",
"order": 2,
"value": "16 January 2024"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Accepted",
"name": "accepted",
"order": 3,
"value": "13 March 2024"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "First Online",
"name": "first_online",
"order": 4,
"value": "26 April 2024"
},
{
"group": {
"label": "Declarations",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 1
},
{
"group": {
"label": "Conflict of interest",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 2,
"value": "Authors declare there are no financial competing interest which can impact the work in the manuscript."
}
],
"author": [
{
"affiliation": [],
"family": "Nalban",
"given": "Nasiruddin",
"sequence": "first"
},
{
"affiliation": [],
"family": "Wanjari",
"given": "Manish",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Kolhe",
"given": "Rasika",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Tamboli",
"given": "Munaf",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jamadagni",
"given": "Pallavi",
"sequence": "additional"
}
],
"container-title": "Journal of Proteins and Proteomics",
"container-title-short": "J Proteins Proteom",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"link.springer.com"
]
},
"created": {
"date-parts": [
[
2024,
4,
26
]
],
"date-time": "2024-04-26T16:01:45Z",
"timestamp": 1714147305000
},
"deposited": {
"date-parts": [
[
2024,
4,
26
]
],
"date-time": "2024-04-26T16:26:33Z",
"timestamp": 1714148793000
},
"indexed": {
"date-parts": [
[
2024,
4,
27
]
],
"date-time": "2024-04-27T00:25:18Z",
"timestamp": 1714177518526
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2024,
4,
26
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
4,
26
]
],
"date-time": "2024-04-26T00:00:00Z",
"timestamp": 1714089600000
}
},
{
"URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
4,
26
]
],
"date-time": "2024-04-26T00:00:00Z",
"timestamp": 1714089600000
}
}
],
"link": [
{
"URL": "https://link.springer.com/content/pdf/10.1007/s42485-024-00136-w.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://link.springer.com/article/10.1007/s42485-024-00136-w/fulltext.html",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://link.springer.com/content/pdf/10.1007/s42485-024-00136-w.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "297",
"original-title": [],
"prefix": "10.1007",
"published": {
"date-parts": [
[
2024,
4,
26
]
]
},
"published-online": {
"date-parts": [
[
2024,
4,
26
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"DOI": "10.1080/07391102.2020.1762741",
"author": "I Abdelli",
"doi-asserted-by": "publisher",
"first-page": "3263",
"issue": "9",
"journal-title": "J Biomol Struct Dyn",
"key": "136_CR1",
"unstructured": "Abdelli I, Hassani F, Bekkel Brikci S, Ghalem S (2021) In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria. J Biomol Struct Dyn 39(9):3263–3276. https://doi.org/10.1080/07391102.2020.1762741",
"volume": "39",
"year": "2021"
},
{
"DOI": "10.1016/j.ijbiomac.2020.07.235",
"author": "O Abian",
"doi-asserted-by": "publisher",
"first-page": "1693",
"journal-title": "Int J Biol Macromol",
"key": "136_CR2",
"unstructured": "Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita L, Vega S, Reyburn HT, Rizzuti B, Velazquez-Campoy A (2020) Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int J Biol Macromol 164:1693–1703. https://doi.org/10.1016/j.ijbiomac.2020.07.235",
"volume": "164",
"year": "2020"
},
{
"DOI": "10.1016/j.compbiomed.2022.105452",
"author": "Ş Adem",
"doi-asserted-by": "publisher",
"journal-title": "Comput Biol Med",
"key": "136_CR3",
"unstructured": "Adem Ş, Eyupoglu V, Ibrahim IM, Sarfraz I, Rasul A, Ali M, Elfiky AA (2022) Multidimensional in silico strategy for identification of natural polyphenols-based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19. Comput Biol Med 145:105452. https://doi.org/10.1016/j.compbiomed.2022.105452",
"volume": "145",
"year": "2022"
},
{
"key": "136_CR4",
"unstructured": "Agnivesh. 2007. Charaka Samhita with ‘Ayurveda-Deepika’ commentary of Chakrapanidatta. Chowkhamba Sanskrit Sansthana, Varanasi, India. 25/40. P.n.140"
},
{
"DOI": "10.1177/1934578X231166283",
"author": "PK Agrawal",
"doi-asserted-by": "publisher",
"first-page": "1934",
"issue": "4",
"journal-title": "Nat Prod Commun",
"key": "136_CR5",
"unstructured": "Agrawal PK, Agrawal C, Blunden G (2023) Antiviral and possible prophylactic significance of myricetin for COVID-19. Nat Prod Commun 18(4):1934. https://doi.org/10.1177/1934578X231166283",
"volume": "18",
"year": "2023"
},
{
"DOI": "10.33263/BRIAC115.1333313346",
"author": "S Albayrak",
"doi-asserted-by": "publisher",
"first-page": "13333",
"issue": "5",
"journal-title": "Biointerface Res Appl Chem",
"key": "136_CR6",
"unstructured": "Albayrak S, Gök Y, Sari Y, Tok TT, Aktaş A (2021) Benzimidazolium salts bearing 2-methyl-1, 4-benzodioxane group: synthesis, characterization, computational studies, in vitro antioxidant and antimicrobial activity vitro antioxidant and antimicrobial activity. Biointerface Res Appl Chem 11(5):13333–13346. https://doi.org/10.33263/BRIAC115.1333313346",
"volume": "11",
"year": "2021"
},
{
"DOI": "10.1016/j.biopha.2022.112658",
"author": "S Ali",
"doi-asserted-by": "publisher",
"journal-title": "Biomed Pharmacother",
"key": "136_CR7",
"unstructured": "Ali S, Alam M, Khatoon F, Fatima U, Elasbali AM, Adnan M, Islam A, Hassan MI, Snoussi M, De Feo V (2022) Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights. Biomed Pharmacother 147:112658. https://doi.org/10.1016/j.biopha.2022.112658",
"volume": "147",
"year": "2022"
},
{
"DOI": "10.1016/j.bpj.2014.12.047",
"author": "R Anandakrishnan",
"doi-asserted-by": "publisher",
"first-page": "1153",
"issue": "5",
"journal-title": "Biophys J",
"key": "136_CR8",
"unstructured": "Anandakrishnan R, Drozdetski A, Walker RC, Onufriev AV (2015) Speed of conformational change: comparing explicit and implicit solvent molecular dynamics simulations. Biophys J 108(5):1153–1164. https://doi.org/10.1016/j.bpj.2014.12.047",
"volume": "108",
"year": "2015"
},
{
"DOI": "10.1016/j.jep.2009.02.041",
"author": "NP Babu",
"doi-asserted-by": "publisher",
"first-page": "356",
"issue": "2",
"journal-title": "J Ethnopharmacol",
"key": "136_CR9",
"unstructured": "Babu NP, Pandikumar P, Ignacimuthu S (2009) Anti-inflammatory activity of Albizia lebbeck Benth. an ethnomedicinal plant, in acute and chronic animal models of inflammation. J Ethnopharmacol 125(2):356–360. https://doi.org/10.1016/j.jep.2009.02.041",
"volume": "125",
"year": "2009"
},
{
"DOI": "10.1021/ja0527525",
"author": "E Barratt",
"doi-asserted-by": "publisher",
"first-page": "11827",
"issue": "33",
"journal-title": "J Am Chem Soc",
"key": "136_CR10",
"unstructured": "Barratt E, Bingham RJ, Warner DJ, Laughton CA, Phillips SE, Homans SW (2005) Van der Waals interactions dominate ligand− protein association in a protein binding site occluded from solvent water. J Am Chem Soc 127(33):11827–11834. https://doi.org/10.1021/ja0527525",
"volume": "127",
"year": "2005"
},
{
"DOI": "10.3390/antibiotics11111614",
"author": "K Bijelić",
"doi-asserted-by": "publisher",
"first-page": "1614",
"issue": "11",
"journal-title": "Antibiotics",
"key": "136_CR11",
"unstructured": "Bijelić K, Hitl M, Kladar N (2022) Phytochemicals in the prevention and treatment of SARS-CoV-2 clinical evidence. Antibiotics 11(11):1614. https://doi.org/10.3390/antibiotics11111614",
"volume": "11",
"year": "2022"
},
{
"DOI": "10.1371/journal.pone.0248479",
"author": "S Borse",
"doi-asserted-by": "publisher",
"issue": "6",
"journal-title": "PLoS ONE",
"key": "136_CR12",
"unstructured": "Borse S, Joshi M, Saggam A, Bhat V, Walia S, Marathe A, Sagar S, Chavan-Gautam P, Girme A, Hingorani L, Tillu G (2021) Ayurveda botanicals in COVID-19 management: an in silico multi-target approach. PLoS ONE 16(6):e0248479. https://doi.org/10.1371/journal.pone.0248479",
"volume": "16",
"year": "2021"
},
{
"DOI": "10.3390/v14071458",
"author": "OA Chaves",
"doi-asserted-by": "publisher",
"first-page": "1458",
"issue": "7",
"journal-title": "Viruses",
"key": "136_CR13",
"unstructured": "Chaves OA, Fintelman-Rodrigues N, Wang X, Sacramento CQ, Temerozo JR, Ferreira AC, Mattos M, Pereira-Dutra F, Bozza PT, Castro-Faria-Neto HC, Russo JJ (2022) Commercially available flavonols are better SARS-CoV-2 inhibitors than isoflavone and flavones. Viruses 14(7):1458. https://doi.org/10.3390/v14071458",
"volume": "14",
"year": "2022"
},
{
"DOI": "10.1038/s41579-018-0118-9",
"author": "J Cui",
"doi-asserted-by": "publisher",
"first-page": "181",
"issue": "3",
"journal-title": "Nat Rev Microbiol",
"key": "136_CR14",
"unstructured": "Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17(3):181–192. https://doi.org/10.1038/s41579-018-0118-9",
"volume": "17",
"year": "2019"
},
{
"DOI": "10.1016/j.jep.2018.11.004",
"author": "TH Desai",
"doi-asserted-by": "publisher",
"first-page": "494",
"journal-title": "J Ethnopharmacol",
"key": "136_CR15",
"unstructured": "Desai TH, Joshi SV (2019) Anticancer activity of saponin isolated from Albizia lebbeck using various in vitro models. J Ethnopharmacol 231:494–502. https://doi.org/10.1016/j.jep.2018.11.004",
"volume": "231",
"year": "2019"
},
{
"DOI": "10.2147/IJGM.S318720",
"author": "F Di Pierro",
"doi-asserted-by": "publisher",
"journal-title": "Int J General Med",
"key": "136_CR16",
"unstructured": "Di Pierro F, Derosa G, Maffioli P, Bertuccioli A, Togni S, Riva A, Allegrini P, Khan A, Khan S, Khan BA, Altaf N (2021) Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study. Int J General Med. https://doi.org/10.2147/IJGM.S318720",
"year": "2021"
},
{
"DOI": "10.1016/j.heliyon.2023.e13952",
"author": "HV Edwin",
"doi-asserted-by": "publisher",
"journal-title": "Heliyon",
"key": "136_CR17",
"unstructured": "Edwin HV, Antony CS (2023) An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. https://doi.org/10.1016/j.heliyon.2023.e13952",
"year": "2023"
},
{
"DOI": "10.3390/ph15091049",
"author": "A Gasmi",
"doi-asserted-by": "publisher",
"first-page": "1049",
"issue": "9",
"journal-title": "Pharmaceuticals",
"key": "136_CR18",
"unstructured": "Gasmi A, Mujawdiya PK, Lysiuk R, Shanaida M, Peana M, Gasmi Benahmed A, Beley N, Kovalska N, Bjørklund G (2022) Quercetin in the prevention and treatment of coronavirus infections: a focus on SARS-CoV-2. Pharmaceuticals 15(9):1049. https://doi.org/10.3390/ph15091049",
"volume": "15",
"year": "2022"
},
{
"DOI": "10.5114/bta.2021.108722",
"author": "S Ghosh",
"doi-asserted-by": "publisher",
"first-page": "257",
"issue": "3",
"journal-title": "Biotechnologia",
"key": "136_CR19",
"unstructured": "Ghosh S, Chetia D, Gogoi N, Rudrapal M (2021) Design, molecular docking, drug-likeness, and molecular dynamics studies of 1, 2, 4-trioxane derivatives as novel Plasmodium falciparum falcipain-2 (FP-2) inhibitors. Biotechnologia 102(3):257. https://doi.org/10.5114/bta.2021.108722",
"volume": "102",
"year": "2021"
},
{
"DOI": "10.1007/s11030-021-10211-9",
"author": "B Gogoi",
"doi-asserted-by": "publisher",
"first-page": "1963",
"journal-title": "Mol Divers",
"key": "136_CR20",
"unstructured": "Gogoi B, Chowdhury P, Goswami N, Gogoi N, Naiya T, Chetia P, Mahanta S, Chetia D, Tanti B, Borah P, Handique PJ (2021) Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation. Mol Divers 25:1963–1977. https://doi.org/10.1007/s11030-021-10211-9",
"volume": "25",
"year": "2021"
},
{
"DOI": "10.1016/B978-0-12-821038-3.00007-0",
"author": "K Gulati",
"doi-asserted-by": "publisher",
"first-page": "101",
"key": "136_CR21",
"unstructured": "Gulati K, Verma P, Rai N, Ray A (2021) Role of nutraceuticals in respiratory and allied diseases. nutraceuticals. Academic Press, Cham, pp 101–115. https://doi.org/10.1016/B978-0-12-821038-3.00007-0",
"volume-title": "nutraceuticals",
"year": "2021"
},
{
"DOI": "10.3390/ijms21113922",
"author": "M Hagar",
"doi-asserted-by": "publisher",
"first-page": "3922",
"issue": "11",
"journal-title": "Int J Mol Sci",
"key": "136_CR22",
"unstructured": "Hagar M, Ahmed HA, Aljohani G, Alhaddad OA (2020) Investigation of some antiviral N-heterocycles as COVID 19 drug: molecular docking and DFT calculations. Int J Mol Sci 21(11):3922. https://doi.org/10.3390/ijms21113922",
"volume": "21",
"year": "2020"
},
{
"key": "136_CR23",
"unstructured": "https://www.worldometers.info/coronavirus"
},
{
"author": "M Jaiswal",
"first-page": "67",
"issue": "3",
"journal-title": "AYU (int Q J Res Ayurveda)",
"key": "136_CR24",
"unstructured": "Jaiswal M, Prajapati PK, Patgiri BJ, Ravishankar B (2006) A comparative pharmaco-clinical study on anti-asthmatic effect of Shirisharishta prepared by bark, sapwood and heartwood of Albizia Lebbeck. AYU (int Q J Res Ayurveda) 27(3):67",
"volume": "27",
"year": "2006"
},
{
"DOI": "10.1002/uog.22088",
"author": "J Juan",
"doi-asserted-by": "publisher",
"first-page": "15",
"issue": "1",
"journal-title": "Ultrasound Obstet Gynecol",
"key": "136_CR25",
"unstructured": "Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC (2020) Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet Gynecol 56(1):15–27. https://doi.org/10.1002/uog.22088",
"volume": "56",
"year": "2020"
},
{
"DOI": "10.1016/S2221-1691(12)60251-2",
"author": "DK Kajaria",
"doi-asserted-by": "publisher",
"first-page": "905",
"issue": "11",
"journal-title": "Asian Pac J Trop Biomed",
"key": "136_CR26",
"unstructured": "Kajaria DK, Gangwar M, Kumar D, Sharma AK, Tilak R, Nath G, Tripathi YB, Tripathi JS, Tiwari SK (2012) Evaluation of antimicrobial activity and bronchodialator effect of a polyherbal drug–Shrishadi. Asian Pac J Trop Biomed 2(11):905–909. https://doi.org/10.1016/S2221-1691(12)60251-2",
"volume": "2",
"year": "2012"
},
{
"DOI": "10.1007/s10238-006-0114-7",
"author": "D Kempuraj",
"doi-asserted-by": "publisher",
"first-page": "150",
"journal-title": "Clin Exp Med",
"key": "136_CR27",
"unstructured": "Kempuraj D, Castellani ML, Petrarca C, Frydas S, Conti P, Theoharides TC, Vecchiet J (2006) Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line. Clin Exp Med 6:150–156. https://doi.org/10.1007/s10238-006-0114-7",
"volume": "6",
"year": "2006"
},
{
"DOI": "10.1038/s41598-017-09941-4",
"author": "P Khan",
"doi-asserted-by": "publisher",
"first-page": "9470",
"issue": "1",
"journal-title": "Sci Rep",
"key": "136_CR28",
"unstructured": "Khan P, Rahman S, Queen A, Manzoor S, Naz F, Hasan GM, Luqman S, Kim J, Islam A, Ahmad F, Hassan MI (2017) Elucidation of dietary polyphenolics as potential inhibitor of microtubule affinity regulating kinase 4: in silico and in vitro studies. Sci Rep 7(1):9470. https://doi.org/10.1038/s41598-017-09941-4",
"volume": "7",
"year": "2017"
},
{
"author": "S Kumar",
"first-page": "48",
"issue": "1",
"journal-title": "Int J Pharm Sci Drug Res",
"key": "136_CR29",
"unstructured": "Kumar S, Bansal P, Gupta V, Sannd R, Rao M (2010) The clinical effect of Albizia lebbeck stem bark decoction on bronchial asthma. Int J Pharm Sci Drug Res 2(1):48–50",
"volume": "2",
"year": "2010"
},
{
"DOI": "10.1016/j.apsusc.2020.146028",
"author": "K Li",
"doi-asserted-by": "publisher",
"journal-title": "Appl Surf Sci",
"key": "136_CR30",
"unstructured": "Li K, Li N, Yan N, Wang T, Zhang Y, Song Q, Li H (2020) Adsorption of small hydrocarbons on pristine, N-doped and vacancy graphene by DFT study. Appl Surf Sci 515:146028. https://doi.org/10.1016/j.apsusc.2020.146028",
"volume": "515",
"year": "2020"
},
{
"DOI": "10.1016/j.jpha.2021.09.009",
"author": "SH Manjunath",
"doi-asserted-by": "publisher",
"first-page": "29",
"issue": "1",
"journal-title": "J Pharm Anal",
"key": "136_CR31",
"unstructured": "Manjunath SH, Thimmulappa RK (2022) Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. J Pharm Anal 12(1):29–34. https://doi.org/10.1016/j.jpha.2021.09.009",
"volume": "12",
"year": "2022"
},
{
"DOI": "10.1039/C4NP00085D",
"author": "JP Martinez",
"doi-asserted-by": "publisher",
"first-page": "29",
"issue": "1",
"journal-title": "Nat Prod Rep",
"key": "136_CR32",
"unstructured": "Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A (2015) Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep 32(1):29–48. https://doi.org/10.1039/C4NP00085D",
"volume": "32",
"year": "2015"
},
{
"DOI": "10.1080/07391102.2021.1936183",
"author": "S Mathpal",
"doi-asserted-by": "publisher",
"first-page": "9885",
"issue": "20",
"journal-title": "J Biomol Struct Dyn",
"key": "136_CR33",
"unstructured": "Mathpal S, Sharma P, Joshi T, Joshi T, Pande V, Chandra S (2022) Screening of potential bio-molecules from Moringa olifera against SARS-CoV-2 main protease using computational approaches. J Biomol Struct Dyn 40(20):9885–9896. https://doi.org/10.1080/07391102.2021.1936183",
"volume": "40",
"year": "2022"
},
{
"DOI": "10.26717/BJSTR.2022.41.006618",
"author": "P Mishra",
"doi-asserted-by": "publisher",
"first-page": "32801",
"issue": "3",
"journal-title": "Biomed J Sci Tech Res.",
"key": "136_CR34",
"unstructured": "Mishra P, Shree P, Pandey N, Tripathi YB (2022) Bio actives from Albizia Lebbeck on acute lung injury-acute respiratory distress syndrome molecular targets-in-silico study. Biomed J Sci Tech Res. 41(3):32801–32807. https://doi.org/10.26717/BJSTR.2022.41.006618",
"volume": "41",
"year": "2022"
},
{
"DOI": "10.1038/s42003-020-01577-x",
"author": "V Mody",
"doi-asserted-by": "publisher",
"first-page": "93",
"issue": "1",
"journal-title": "Commun Biol",
"key": "136_CR35",
"unstructured": "Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MC, Fortin GM, Rayalam S, Taval S (2021) Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 4(1):93. https://doi.org/10.1038/s42003-020-01577-x",
"volume": "4",
"year": "2021"
},
{
"DOI": "10.1002/cbic.202000047",
"author": "JS Morse",
"doi-asserted-by": "publisher",
"first-page": "730",
"issue": "5",
"journal-title": "ChemBioChem",
"key": "136_CR36",
"unstructured": "Morse JS, Lalonde T, Xu S, Liu WR (2020) Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 21(5):730–738. https://doi.org/10.1002/cbic.202000047",
"volume": "21",
"year": "2020"
},
{
"DOI": "10.1038/s41586-022-05522-2",
"author": "W Msemburi",
"doi-asserted-by": "publisher",
"first-page": "130",
"issue": "7942",
"journal-title": "Nature",
"key": "136_CR37",
"unstructured": "Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J (2023) The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613(7942):130–137. https://doi.org/10.1038/s41586-022-05522-2",
"volume": "613",
"year": "2023"
},
{
"DOI": "10.7324/JAPS.2023.130209",
"author": "V Nishinarizki",
"doi-asserted-by": "publisher",
"first-page": "078",
"issue": "2",
"journal-title": "J Appl Pharm Sci",
"key": "136_CR38",
"unstructured": "Nishinarizki V, Hardianto A, Gaffar S, Muchtaridi M, Herlina T (2023) Virtual screening campaigns and ADMET evaluation to unlock the potency of flavonoids from Erythrina as 3CLpro SARS-COV-2 inhibitors. J Appl Pharm Sci 13(2):078–088. https://doi.org/10.7324/JAPS.2023.130209",
"volume": "13",
"year": "2023"
},
{
"DOI": "10.1126/science.abl4784",
"author": "DR Owen",
"doi-asserted-by": "publisher",
"first-page": "1586",
"issue": "6575",
"journal-title": "Science",
"key": "136_CR39",
"unstructured": "Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A (2021) An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374(6575):1586–1593. https://doi.org/10.1126/science.abl4784",
"volume": "374",
"year": "2021"
},
{
"DOI": "10.1016/j.molstruc.2022.134390",
"author": "S Padhi",
"doi-asserted-by": "publisher",
"journal-title": "J Mol Struct",
"key": "136_CR40",
"unstructured": "Padhi S, Masi M, Mohanta YK, Saravanan M, Sharma S, Cimmino A, Shanmugarajan D, Evidente A, Tayung K, Rai AK (2023) In silico pharmacokinetics, molecular docking and dynamic simulation studies of endolichenic fungi secondary metabolites: an implication in identifying novel kinase inhibitors as potential anticancer agents. J Mol Struct 1273:134390. https://doi.org/10.1016/j.molstruc.2022.134390",
"volume": "1273",
"year": "2023"
},
{
"DOI": "10.1080/07391102.2020.1757510",
"author": "S Pant",
"doi-asserted-by": "publisher",
"journal-title": "J Biomol Struct Dyn",
"key": "136_CR41",
"unstructured": "Pant S, Singh M, Ravichandiran V, Murty US, Srivastava HK (2020) Peptide-like and small-molecule inhibitors against Covid-19. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1757510",
"year": "2020"
},
{
"DOI": "10.1080/07391102.2020.1762741",
"author": "SK Sinha",
"doi-asserted-by": "publisher",
"first-page": "3244",
"issue": "9",
"journal-title": "J Biomol Struct Dyn",
"key": "136_CR42",
"unstructured": "Sinha SK, Shakya A, Prasad SK, Singh S, Gurav NS, Prasad RS, Gurav SS (2021) An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets. J Biomol Struct Dyn 39(9):3244–3255. https://doi.org/10.1080/07391102.2020.1762741",
"volume": "39",
"year": "2021"
},
{
"DOI": "10.1016/j.crgsc.2021.100202",
"author": "BM Sivani",
"doi-asserted-by": "publisher",
"journal-title": "Curr Res Green Sustain Chem",
"key": "136_CR43",
"unstructured": "Sivani BM, Venkatesh P, Murthy TK, Kumar SB (2021) In silico screening of antiviral compounds from Moringa oleifera for inhibition of SARS-CoV-2 main protease. Curr Res Green Sustain Chem 4:100202. https://doi.org/10.1016/j.crgsc.2021.100202",
"volume": "4",
"year": "2021"
},
{
"DOI": "10.3978/j.issn.2072-1439.2013.06.02",
"author": "KK To",
"doi-asserted-by": "publisher",
"first-page": "S103",
"issue": "Suppl 2",
"journal-title": "J Thorac Dis",
"key": "136_CR44",
"unstructured": "To KK, Hung IF, Chan JF, Yuen KY (2013) From SARS coronavirus to novel animal and human coronaviruses. J Thorac Dis 5(Suppl 2):S103. https://doi.org/10.3978/j.issn.2072-1439.2013.06.02",
"volume": "5",
"year": "2013"
},
{
"DOI": "10.1002/jcc.21367",
"author": "K Vanommeslaeghe",
"doi-asserted-by": "publisher",
"first-page": "671",
"issue": "4",
"journal-title": "J Comput Chem",
"key": "136_CR45",
"unstructured": "Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I, Mackerell AD Jr (2010) CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31(4):671–690. https://doi.org/10.1002/jcc.21367",
"volume": "31",
"year": "2010"
},
{
"DOI": "10.1016/j.crphar.2021.100038",
"author": "D Verma",
"doi-asserted-by": "publisher",
"journal-title": "Curr Res Pharmacol Drug Discov",
"key": "136_CR46",
"unstructured": "Verma D, Mitra D, Paul M, Chaudhary P, Kamboj A, Thatoi H, Janmeda P, Jain D, Panneerselvam P, Shrivastav R, Pant K (2021) Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/3CLpro: molecular docking and simulation studies of three pertinent medicinal plant natural components. Curr Res Pharmacol Drug Discov 2:100038. https://doi.org/10.1016/j.crphar.2021.100038",
"volume": "2",
"year": "2021"
},
{
"DOI": "10.13040/IJPSR.0975-8232.5(11).5040-49",
"author": "M Yim",
"doi-asserted-by": "publisher",
"first-page": "5042",
"issue": "11",
"journal-title": "Int J Pharm Sci Res",
"key": "136_CR47",
"unstructured": "Yim M, Sarma BP, Sinha S, Deka H, Deka H, Parida P, Ghosh A, Johari S (2014) exploring the possible mechanism of Albizzia lebbeck components binding with drug targets of bronchial asthma–an insilico and clinical analysis. Int J Pharm Sci Res 5(11):5042–5051. https://doi.org/10.13040/IJPSR.0975-8232.5(11).5040-49",
"volume": "5",
"year": "2014"
},
{
"DOI": "10.1371/journal.pone.0039546",
"author": "JL Zhang",
"doi-asserted-by": "publisher",
"issue": "6",
"journal-title": "PLoS ONE",
"key": "136_CR48",
"unstructured": "Zhang JL, Zheng QC, Li ZQ, Zhang HX (2012) Molecular dynamics simulations suggest ligand’s binding to nicotinamidase/pyrazinamidase. PLoS ONE 7(6):e39546. https://doi.org/10.1371/journal.pone.0039546",
"volume": "7",
"year": "2012"
},
{
"DOI": "10.1073/pnas.2117142119",
"author": "Y Zhao",
"doi-asserted-by": "publisher",
"issue": "16",
"journal-title": "Proc Natl Acad Sci",
"key": "136_CR49",
"unstructured": "Zhao Y, Zhu Y, Liu X, Jin Z, Duan Y, Zhang Q, Wu C, Feng L, Du X, Zhao J, Shao M (2022) Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. Proc Natl Acad Sci 119(16):e2117142119. https://doi.org/10.1073/pnas.2117142119",
"volume": "119",
"year": "2022"
}
],
"reference-count": 49,
"references-count": 49,
"relation": {},
"resource": {
"primary": {
"URL": "https://link.springer.com/10.1007/s42485-024-00136-w"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Targeting COVID-19 (SARS-CoV-2) main protease through phytochemicals of Albizia lebbeck: molecular docking, molecular dynamics simulation, MM–PBSA free energy calculations, and DFT analysis",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy"
}